SCHEMBL3374527

SCHEMBL3374527

CCOC(=O)C(Cc1ccc(OCc2csc(-c3ccccc3)n2)c(F)c1)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 3/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 2/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
PKM P14618 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.42
PPARG P37231 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369630 0.93 LMNA (0.43) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3372318 0.93 PPARG (0.47) RAB9ANPC1TSHRMAPTL3MBTL1
SCHEMBL3372967 0.91 PTPN2 (0.42) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3373634 0.91 FFAR1 (0.39) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3374570 0.91 MAPT (0.41) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3402718 0.90 ALOX5 (0.49) TP53MAPTLMNAPPARGFFAR1
SCHEMBL3370575 0.90 F2RL3 (0.39) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3375391 0.90 ALOX5 (0.42) SMN1; SMN2TP53ALDH1A1LMNAPPARG
SCHEMBL3371667 0.88 LMNA (0.43) RAB9ASMN1; SMN2NPC1TSHRTP53
SCHEMBL3373587 0.84 LMNA (0.45) RAB9ASMN1; SMN2NPC1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR RAB9A 2319/4885SMN1; SMN2 2045/4885NPC1 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.